Abstract
张顺祥,党如波,张卫东,梁晓峰,崔富强.中国乙型肝炎疫苗免疫预防效果和现行策略的经济学和决策学评估[J].Chinese journal of Epidemiology,2008,29(10):1003-1008
中国乙型肝炎疫苗免疫预防效果和现行策略的经济学和决策学评估
Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China
Received:July 03, 2008  
DOI:
KeyWord: 乙型肝炎  疫苗  决策树  费用效益分析  费用效果分析
English Key Word: Hepatitis B virus  Vaccination  Decision tree  Coat-benefit  Cost-effectiveness
FundProject:深圳市科技计划资助项目(200702146)
Author NameAffiliation
ZHANG Shun-xiang Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China 
DANG Ru-bo 郑州大学公共卫生学院 
ZHANG Wei-dong 郑州大学公共卫生学院 
LIANG Xiao-feng 中国疾病预防控制中心计划免疫规划中心 
CUI Fu-qiang 中国疾病预防控制中心计划免疫规划中心 
Hits: 3998
Download times: 1375
Abstract:
      目的 对中国儿童乙型肝炎(乙肝)疫苗免疫预防14年(1992-2005年)效果评估和对现行的乙肝疫苗接种方案进行优化.方法 构建适合中国乙肝疫苗免疫预防实际效果评估和方案优化决策树模型,模型中参数根据相关研究文献或由专业机构提供.主要分析指标为成本效果比(CER)和效益成本比(BCR),用敏感度分析和阈值分析对各参数影响大小进行评估. 结果 14年间,中国直接和间接地用于新生儿乙肝疫苗接种总投入约为53.48亿元,而获得的总效益达2728.25亿元,即乙肝疫苗接种的净效益为2674.77亿元;同期由于疫苗接种避免发生HBV感染约6523万人,每预防一例HBV感染的费用为81.99元,但每投入1元获得的收益为51.01元.中国现行乙肝疫苗接种采用新生儿3剂5 μg,并于出生24 h内完成第一针;对孕妇筛检HBsAg,阳性者新生儿加注一剂乙肝免疫球蛋白(HBIG)均为最优方案.而新生儿以外的1~60岁人群乙肝疫苗接种仍町以获得正效益,尤其是在20岁以前接种效益更明显;但"筛检后再接种"均优于"直接接种". 结论 中国既往14年间在新生儿中实行的乙肝疫苗接种策略,从实际的预防效果和投资的经济效益看都是值得的;现行的新生儿优先接种并保持高覆盖率的策略仍为合理方案.
English Abstract:
      Objective To evaluate the outcome of hepatitis B vaccination strategies performed over the past 14 years and different alternatives recommended for future immunization programs from the point of view of economic efficacy.Methods Methods used would include:process of decision analysis including building the tree:populating the model with parameters;estimating expected cost benefit and effectiveness and deterministic and probabilistic sensitivity and threshold analysis.Results In China,over the past 14 vears from 1992 to 2005.around 5.348 billion Chinese Yuan were provided for hepatitis B vaccination but the total benefits were 272.825 billion Yuan,with net benefits as 267.477 billion Yuan.The cost for each infection averted was 81.99 Yuan while the benefit of one Yuan being invested had 51.01 Ynan in return.For the future recommendations,data from the study revealed that the priority of hepatitis B vaccination for new borns and vaccinations plus passive immunization of newborns of HBsAg positive mothers were most effective approaches.If the other population as adolescents was included into the vaccination program,then screening for hepatitis B virus markers before accepting the vaccination appeared to be one of the most cost-saving strategies.Sensitivity and threshold analyses showed that hepatitis B virus marker Was the most important factor,followed by the cost of vaccine,vaccination coverage and vaccine efficacy,in order.Conclusion Routine vaccination of infants in successive birth cohorts to prevent HBV transmission was a cost-effective strategy administrated over the past 14 years in China.In the following years,the immunization of newborns was still the preferential strategy from a societal perspective.However,vaccination provided to other population including adolescents seemed economically less attractive.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close